title: Sperm aneuploidy after testicular cancer treatment: data from a prospective multicenter study performed within the French Centre d'Étude et de Conservation des Oeufs et du Sperme network.
abstract: OBJECTIVE
  To study sperm aneuploidy in a population of testicular cancer (TC) patients treated with the use of either bleomycin-etoposide-cisplatin (BEP) chemotherapy or radiotherapy.
  
  
  METHODS
  Multicenter prospective longitudinal study of TC patients analyzed before treatment and after 3, 6, 12, and 24 months (T3-T24).
  
  
  METHODS
  Fifty-four TC patients and a control group of 10 fertile sperm donors.
  
  
  METHODS
  University hospital laboratories.
  
  
  METHODS
  Routine semen analyses; sperm aneuploidy and diploidy.
  
  
  METHODS
  Comparison of sperm characteristics and sperm chromosome abnormalities during TC patient follow-up.
  
  
  RESULTS
  Semen characteristics recovered pretreatment values 12 months after radiotherapy and 24 months after more than two BEP cycles. A significant increase in sperm disomy YY and XX was observed in the TC group before treatment compared with the control group. After more than two BEP cycles, the mean sperm aneuploidy rate increased significantly at T12 and reached the pretreatment value at T24. After radiotherapy, the mean sperm aneuploidy returned to the pretreatment value at T12. At T24, nearly 40% of TC patients did not recover their pretreatment sperm aneuploidy rate.
  
  
  CONCLUSIONS
  Genetic counseling of TC patients should include information on the potential elevated risk of aneuploid conceptus from sperm recovered after treatment and the necessity to postpone conception up to ≥12 months after radiotherapy and ≥24 months after more than two BEP chemotherapy cycles. However, few men receiving one or two BEP cycles and some dropouts are the main limitations of this study.
authors.affiliation: Fédération Française des Centre d'Etude et de Conservation des Œufs et du Sperme Humains (CECOS), Paris, France; Laboratoire de Biologie de la Reproduction-CECOS, CHU-Hôpitaux de Rouen and EA 4308 "Gamétogenèse et Qualité du Gamète," Université de Rouen, Rouen, France. Electronic address: nathalie.rives@chu-rouen.fr.
authors.forename: Nathalie
authors.initials: N
authors.lastname: Rives
authors.affiliation: Université de Toulouse, UPS, Groupe de Recherche en Fertilité Humaine (EA 3694, Human Fertility Research Group), and CECOS, University Hospital, Toulouse, France.
authors.forename: Marie
authors.initials: M
authors.lastname: Walschaerts
authors.affiliation: Fédération Française des Centre d'Etude et de Conservation des Œufs et du Sperme Humains (CECOS), Paris, France; Laboratoire de Biologie de la Reproduction-CECOS, CHU-Hôpitaux de Rouen and EA 4308 "Gamétogenèse et Qualité du Gamète," Université de Rouen, Rouen, France.
authors.forename: Véronique
authors.initials: V
authors.lastname: Setif
authors.affiliation: Fédération Française des Centre d'Etude et de Conservation des Œufs et du Sperme Humains (CECOS), Paris, France; Laboratoire d'Aide à la Procréation-CECOS, Laboratoire AGIM, CNRS-FRE3405, Equipe Génétique-Infertilité-Thérapeutique, Faculté de Médecine de Grenoble, Grenoble, France.
authors.forename: Sylvianne
authors.initials: S
authors.lastname: Hennebicq
authors.affiliation: Fédération Française des Centre d'Etude et de Conservation des Œufs et du Sperme Humains (CECOS), Paris, France; Laboratoire de Biologie de la Reproduction-CECOS, Hôpital la Conception, Marseille, France.
authors.forename: Jacqueline
authors.initials: J
authors.lastname: Saias
authors.affiliation: Fédération Française des Centre d'Etude et de Conservation des Œufs et du Sperme Humains (CECOS), Paris, France; Assistance Médicale à la Procréation, CECOS, CHU Estaing, and Laboratoire Génétique Reproduction et Développement, GReD, UMR CNRS 6293, INSERM U1103, Faculté de Médecine, Université d'Auvergne, Clermont-Ferrand, France.
authors.forename: Florence
authors.initials: F
authors.lastname: Brugnon
authors.affiliation: Fédération Française des Centre d'Etude et de Conservation des Œufs et du Sperme Humains (CECOS), Paris, France; Département d'Histologie-Embryologie, Biologie de la Reproduction-CECOS, Site Port-Royal, Paris Centre University Hospitals, Paris, France.
authors.forename: Jacques
authors.initials: J
authors.lastname: Auger
authors.affiliation: Fédération Française des Centre d'Etude et de Conservation des Œufs et du Sperme Humains (CECOS), Paris, France; Service d'Histologie, Biologie de la Reproduction-CECOS, Hôpital Tenon, Paris, France.
authors.forename: Isabelle
authors.initials: I
authors.lastname: Berthaut
authors.affiliation: Fédération Française des Centre d'Etude et de Conservation des Œufs et du Sperme Humains (CECOS), Paris, France; Unité de BDR-CECOS, Pole de Biologie, CHU Côte de Nacre, Caen, France.
authors.forename: Ethel
authors.initials: E
authors.lastname: Szerman
authors.affiliation: Fédération Française des Centre d'Etude et de Conservation des Œufs et du Sperme Humains (CECOS), Paris, France; Université de Toulouse, UPS, Groupe de Recherche en Fertilité Humaine (EA 3694, Human Fertility Research Group), and CECOS, University Hospital, Toulouse, France.
authors.forename: Myriam
authors.initials: M
authors.lastname: Daudin
authors.affiliation: Fédération Française des Centre d'Etude et de Conservation des Œufs et du Sperme Humains (CECOS), Paris, France; Université de Toulouse, UPS, Groupe de Recherche en Fertilité Humaine (EA 3694, Human Fertility Research Group), and CECOS, University Hospital, Toulouse, France.
authors.forename: Louis
authors.initials: L
authors.lastname: Bujan
mesh_terms: D000328:Adult; D000782:Aneuploidy; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D001761:Bleomycin / Q000009:adverse effects; D016022:Case-Control Studies; D041321:Chromosomes, Human, X; D041322:Chromosomes, Human, Y; D002945:Cisplatin / Q000009:adverse effects; D004171:Diploidy; D005047:Etoposide / Q000009:adverse effects; D005602:France; D006785:Hospitals, University; D006801:Humans; D007248:Infertility, Male / Q000139:chemically induced* / Q000175:diagnosis / Q000235:genetics; D008137:Longitudinal Studies; D008297:Male; D011446:Prospective Studies; D011832:Radiation Injuries / Q000175:diagnosis / Q000209:etiology* / Q000235:genetics; D011878:Radiotherapy / Q000009:adverse effects; D012307:Risk Factors; D055101:Semen Analysis; D013094:Spermatozoa / Q000187:drug effects* / Q000473:pathology / Q000528:radiation effects*; D013736:Testicular Neoplasms / Q000628:therapy*; D013997:Time Factors; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D001761:Bleomycin; D005047:Etoposide; D002945:Cisplatin
keywords: Aneuploidy; chemotherapy; radiotherapy; spermatozoa; testicular cancer